Original Article: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial) nej.md/4ngEZ36 American Diabetes Association - DiabetesPro | #ADASciSessions

Original Article: Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2 phase 3a trial) nej.md/4ehQwLk American Diabetes Association - DiabetesPro | #ADASciSessions

Halls Kaan Akturk, MD, prepares the #ADA2025 audience for the presentation of the ADJUST-T1D trial of semaglutide 1 mg on top of auto insulin delivery in patients with T1D. Stay tuned for more! #ADASciSessions

Which intermittent fasting strategies are better? All intermittent fasting strategies and continuous energy restriction diets reduce body weight Alternate day fasting showed benefit in body weight reduction compared with continuous energy restriction bmj.com/content/bmj/38…

GLP-1 receptor agonist usage is associated with decreased risk of lower extremity amputations, diabetic foot ulcers, and mortality compared to SGLT2 inhibitors in people with type 2 diabetes. ADA Professional Publications Read Here➡️ diabetesjournals.org/care/lookup/do…

ADA consensus report calls for MASLD, liver fibrosis screening in type 2 diabetes | ACP Diabetes Monthly diabetes.acponline.org/archives/2025/…

🫀🧠 2025 ACC Scientific Statement: Management of Obesity in Adults With Heart Failure Obesity is not just a comorbidity-it’s a modifiable treatment target in heart failure. 🔹 Calls for integrated HF & obesity care pathways jacc.org/doi/10.1016/j.… #HeartFailure #Obesity

First GIP/GLP-1 dual agonist tirzepatide showed CV protection in pp type 2 diabetes and heart disease ⁦⁦Eli Lilly and Company⁩ Second: all-cause mortality 16% lower for Mounjaro vs. Trulicity (hazard ratio: 0.84; 95.0% CI: 0.75 to 0.94) investor.lilly.com/news-releases/…

The new metabolic medicines #T2D #obesity and #inflammation cell.com/trends/endocri…

From #T2D to #obesity #CVD #OSA and now #MASH The expanding benefits of GLP-1 medicines novonordisk.com/news-and-media…

In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body-weight reduction in adults without diabetes and with overweight or obesity. Full trial results and Research Summary: nej.md/444aW7f

New FDA-Cleared Product: CGM + AI for Weight Management medscape.com/viewarticle/ne… medscape.com/viewarticle/ne…

❗️Higher dose GLP-1…. Worth the STEP UP?❗️ Once-weekly semaglutide 7·2 mg in adults with obesity 🔸7.2mg vs 2.4mg vs placebo 🔹mean age 47yrs, mean BMI 39.9 🔸-18.7% vs -15.6% vs -3.9% change in body weight 🔹almost half on 7.2mg achieved 20% weight loss 🔸5.4% permanent,

The hold/discontinue GLP-1 before a procedure” has no clothes. Here findings suggest that minimally sedated gastroscopy prior to colonoscopy, routine GLP-1 agonist withholding, and overly restrictive fasting are not required. onlinelibrary.wiley.com/doi/10.1111/jg…

💊 First oral GLP-1 that’s actually a pill (not peptide-in-disguise) ATTAIN-1: P3 #Obesity pop, no #T2D 🔹#orforglipron 36mg ⤵️ weight 11.2% 🔸Perhaps not quite as good as similar studies with semaglutide (~15%) 🔹but no 💉, no 🥶chain, no food rules 👉Sometimes “accessible

❗️REDEFINE-2 results presented #EASD2025 ❗️ 🔹Cagrilintide 2.4mg/semaglutide 2.4mg in those with T2D 🔸Good mix of M:F and ethnicity 🔹mean BMI 36, mean age 56, mean Hba1c 8% 🔸13.7-15.7% wt loss with 1 in 3 achieving Atleast 20% weight loss ❗️ 🔹Improved TIR, normoglycaemia and

American Association of Clinical Endocrinology Consensus Statement On Obesity Congratulations Karl Nadolsky Dr. Spencer Nadolsky Gil Carvalho MD PhD🌈🇵🇸 Matthew Nagra, ND Beverly G. Tchang, MD Michael Mindrum, MD Michael Albert, MD endocrinepractice.org/article/S1530-…

Worth a read for context on the "lean mass muscle loss" #obesity GLP-1 medicine debate. Keep an eye on muscle function and health, diet quality and resistance #exercise and not just the DXA scan Luke Norton Molecular Metabolism #weightloss sciencedirect.com/science/articl…

Are some GLP-1 medicines more cardioprotective than others? #easd25 A new real world study using US Medicare data novonordisk.com/content/nncorp…

Inflammation is a key driver of the pathophysiology of cardiometabolic disorders #obesity #T2D and new metabolic medicines based on GLP-1 action exert their magic in part by reducing inflammation. A new review from Professor Donath summarizes the field sciencedirect.com/science/articl…